• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ANGIOJET; CATHETER, CORONARY, ATHERECTOMY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ANGIOJET; CATHETER, CORONARY, ATHERECTOMY Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Hemolysis (1886); Hemorrhage/Bleeding (1888)
Event Date 09/22/2020
Event Type  Injury  
Manufacturer Narrative
Date of event estimated using date journal article was published.Initial reporter address 1: (b)(6).Initial reporter facility name: department of interventional vascular surgery, (b)(6) medicaluniversity hospital.
 
Event Description
It was reported via journal article that patient complications occurred.The objective of this study was to evaluate the efficacy and safety in patients with acute lower extremity deep venous thrombosis who underwent pharmacomechanical thrombectomy (pmt, angiojet mechanical thrombus aspiration).In this retrospective, 424 consecutive patients with acute lower extremity deep venous thrombosis from three institutions were enrolled in the study from january 2015 to december 2018.Of these, patients were divided into two groups, angiojet group and catheter-directed thrombolysis (cdt) group (n=238).Evaluation indexes including limb circumference difference, length of stay (los), urokinase dosage, periprocedural complications, follow-up imaging findings and villalta scores were analyzed from the medical records.A total of 424 patients diagnosed with acute lower extremity deep venous thrombosis were collected in this study.These patients were categorized into angiojet group and cdt group.Significant differences were observed between the two groups with respect to the thigh circumference difference , calf circumference difference, thigh detumescence rate and calf detumescence rate.The mean dose of urokinase in angiojet group was 95.16, 45.89 million iu significantly less than that in the cdt group 293.76, 42.71 million iu (p=0.00).The overall bleeding complication rate was 9.91% (19 patients in angiojet group and 23 patients in cdt group), which included three major (0.71%, 3/424) and 39 minor (9.2%,39/424) events.In the angiojet group, serum creatinine (scr) concentration and urine erythrocyte from the hemolysis caused by the mechanical process were higher than baseline data at admission (p=0.00, p=0.00).The postoperative red blood cell and hemoglobin in two groups were lower than baseline data (p=0.00, p=0.00).Compared with cdt, angiojet thrombectomy has significantly lower estimated incidence of pts in the follow-up.Angiojet thrombectomy has stronger clearance ability for acute lower extremity deep venous thrombosis leading to significant reduction in the consumption of hospital resources, total dose of thrombolytic agents, and infusion time, thereby preventing adverse bleeding events, but patients with renal insufficiency should be careful.Ideal short-term and medium-term efficacy and safety are certain.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ANGIOJET
Type of Device
CATHETER, CORONARY, ATHERECTOMY
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer Contact
jay johnson
two scimed place
maple grove, MN 55311
7634942574
MDR Report Key14804199
MDR Text Key295027542
Report Number2134265-2022-06744
Device Sequence Number1
Product Code MCX
Combination Product (y/n)N
Reporter Country CodeCH
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 06/24/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 05/27/2022
Initial Date FDA Received06/24/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-